Forrest Trivedi J. de Knegt Okusanya

140 SCIENTIFIC SESSIONS September 9-12 | A-1264 PK and Bactericidal Activity in Sputum and Blood of PNU- 100480 Sutezolid, U-480 and its Major Metabolite PNU- 101603, U-603 in Patients with Pulmonary TB

R. S. Wallis

1 , S. O. Friedrich 2 , A. H. Diacon 2 , R. Dawson 3 , A. Venter 2 , D. Paige 1 , T. Zhu 1 , A. Silvia 1 , J. Gobey 1 , C. Ellery 1 , Y. Zhang 1 ; 1 Pfizer, Gro- ton, CT, 2 Stellenbosch Univ., Stellenbosch, South Africa, 3 Univ. Cape Town, Cape Town, South Africa. A-1265 Pharmacodynamics of PNU-100480 U, Sutezolid, a New Oxazolidinone, in Combination with its Active Metabolite in the Killing of Mycobacterium tuberculosis Mtb in an In Vitro Hollow Fiber Infection Model HFIM

A. Louie, D. Brown, K. Files, M. Swift, S. Fikes, G. Drusano; Univ. of Florida, Orlando, FL.

A-1266 A New Mathematical Model for Anti-Infective Pharma- cokineticsPharmacodynamics PKPD which Accommodates Random Mutations

A. Forrest

1,2 , O. O. Okusanya 1,2 , J. B. Bulitta 3 ; 1 SUNY Sch. of Pharmacy, Buffalo, NY, 2 ICPD, Latham, NY, 3 Monash Univ., Melbourne, Australia. A-1267 Tissue Distribution and Macrophages Uptake for Novel Spectinamide Drug Candidates against Tuberculosis

A. Trivedi

1 , D. Madhura 1 , J. Liu 2 , K. Kromke 1 , C. Rathi 1 , V. Loveless 1 , R. E. Lee 2 , B. Meibohm 1 ; 1 Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN, 2 St. Jude Children’s Res. Hosp., Memphis, TN. A-1268 Increasing Rifampicin Dosage in the Treatment of Murine Tuberculosis Allows Reduction of Therapy Duration

G. J. de Knegt

1 , R. E. Aarnoutse 2 , M. T. Ten Kate 1 , M. J. Boeree 2 , D. van Soolingen 3 , I. A. Bakker-Woudenberg 1 , J. E. M. de Steenwinkel 1 ; 1 Erasmus Univ. Med. Ctr., Rotterdam, Netherlands, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3 Natl. Inst. of Publ. Hlth. and the Environ- ment, Bilthoven, Netherlands. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 162A Poster Session Clinical Pharmacology of Novel Anti-Infective Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1269 Population Pharmacokinetic PPK and Pharmacokinetic Pharmacodynamic PKPD Target Attainment TA Analyses for Solithromycin SOL, CEM-101 to Support Intravenous IV Dose Selection in Patients with Community-Acquired Bacterial Pneumonia CABP O. O. Okusanya 1 , S. M. Bhavnani 1 , A. Forrest 1 , C. C. Bulik